Who are Emapalumab-Lzsg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gamifant, Prograf, Interferon Gamma 1-b.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/emapalumab-lzsg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Emapalumab-Lzsg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Emapalumab-Lzsg (Emapalumab-Lzsg) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon gamma Blocker [EPC]. Area: Immunology.

discontinued Interferon gamma Blocker [EPC] Interferon gamma Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Emapalumab-Lzsg (Emapalumab-Lzsg) — Swedish Orphan Biovitrum. 12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Emapalumab-Lzsg TARGET	Emapalumab-Lzsg	Swedish Orphan Biovitrum	discontinued	Interferon gamma Blocker [EPC]	Interferon gamma
Gamifant	EMAPALUMAB	Novimmune S.A.	marketed	Interferon gamma Blocker [EPC]	Interferon gamma	2018-01-01
Prograf	TACROLIMUS	Astellas Pharma	marketed	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01
Interferon Gamma 1-b	Interferon Gamma 1-b	Assistance Publique - Hôpitaux de Paris	phase 3	Cytokine / Immunomodulator	Interferon gamma receptor (IFNGR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-08-30 — Prograf · 8685998 · Formulation · US
2028-08-30 — Prograf · 8664239 · Method of Use · US

Sponsor landscape (Interferon gamma Blocker [EPC] class)

Novimmune S.A. · 1 drug in this class
Swedish Orphan Biovitrum · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Emapalumab-Lzsg — Competitive Intelligence Brief. https://druglandscape.com/ci/emapalumab-lzsg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab